{
    "abstract": "Multiple biologic treatments are licensed for psoriasis. The lack of head-to-head randomized controlled trials makes choosing between them difficult for patients, clinicians, and guideline developers. To establish their relative efficacy and tolerability, we searched MEDLINE, PubMed, Embase, and Cochrane for randomized controlled trials of licensed biologic treatments for skin psoriasis. We performed a network meta-analysis to identify direct and indirect evidence comparing biologics with one another, methotrexate, or placebo. We combined this with hierarchical cluster analysis to consider multiple outcomes related to efficacy and tolerability in combination for each treatment. Study quality, heterogeneity, and inconsistency were evaluated. Direct comparisons from 41 randomized controlled trials (20,561 participants) were included. All included biologics were efficacious compared with placebo or methotrexate at 3\u20134 months. Overall, cluster analysis showed adalimumab, secukinumab, and ustekinumab were comparable in terms of high efficacy and tolerability. Ixekizumab and infliximab were differentiated by very high efficacy but poorer tolerability. The lack of longer term controlled data limited our analysis to short-term outcomes. Trial performance may not equate to real-world performance, and so results need to be considered alongside real-world, long-term safety and effectiveness data. These data suggest that it is possible to discriminate between biologics to inform clinical practice and decision making (PROSPERO 2015:CRD42015017538).",
    "bib_entries": {
        "bib1": {
            "authors": [
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Bansback"
                },
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Sizto"
                },
                {
                    "first": "Huiying",
                    "initial": "H.",
                    "last": "Sun"
                },
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Feldman"
                },
                {
                    "first": "Mary Kaye",
                    "initial": "M.K.",
                    "last": "Willian"
                },
                {
                    "first": "Aslam",
                    "initial": "A.",
                    "last": "Anis"
                }
            ],
            "doi": "10.1159/000233234",
            "firstpage": "209",
            "issn": "10188665",
            "lastpage": "218",
            "pmid": "19657180",
            "pub_year": 2009,
            "title": "Efficacy of systemic treatments for moderate to severe plaque psoriasis: Systematic review and meta-analysis",
            "volume": "219"
        },
        "bib10": {
            "authors": [
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "G\u00f3mez-Garc\u00eda"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Epstein"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Isla-Tejera"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Lorente"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "V\u00e9lez Garc\u00eda-Nieto"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Ruano"
                }
            ],
            "doi": "10.1111/bjd.14814",
            "firstpage": "594",
            "issn": "00070963",
            "lastpage": "603",
            "pmid": "27292159",
            "pub_year": 2017,
            "title": "Short-term efficacy and safety of new biological agents targeting the interleukin-23\u2013T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis",
            "volume": "176"
        },
        "bib11": {
            "authors": [
                {
                    "first": "Christopher E.M.",
                    "initial": "C.E.M.",
                    "last": "Griffiths"
                },
                {
                    "first": "Michael R.",
                    "initial": "M.R.",
                    "last": "Barnes"
                },
                {
                    "first": "A. David",
                    "initial": "A.D.",
                    "last": "Burden"
                },
                {
                    "first": "Frank O.",
                    "initial": "F.O.",
                    "last": "Nestle"
                },
                {
                    "first": "Nick J.",
                    "initial": "N.J.",
                    "last": "Reynolds"
                },
                {
                    "first": "Catherine H.",
                    "initial": "C.H.",
                    "last": "Smith"
                },
                {
                    "first": "Richard B.",
                    "initial": "R.B.",
                    "last": "Warren"
                },
                {
                    "first": "Jonathan N.W.N.",
                    "initial": "J.N.W.N.",
                    "last": "Barker"
                }
            ],
            "doi": "10.1038/jid.2015.286",
            "firstpage": "2903",
            "issn": "0022202X",
            "lastpage": "2907",
            "pmid": "26569580",
            "pub_year": 2015,
            "title": "Establishing an academic-industrial stratified medicine consortium: Psoriasis stratification to optimize relevant therapy",
            "volume": "135"
        },
        "bib12": {
            "authors": [
                {
                    "first": "Julian P.T.",
                    "initial": "J.P.T.",
                    "last": "Higgins"
                },
                {
                    "first": "Douglas G.",
                    "initial": "D.G.",
                    "last": "Altman"
                },
                {
                    "first": "Peter C.",
                    "initial": "P.C.",
                    "last": "G\u00f8tzsche"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "J\u00fcni"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Moher"
                },
                {
                    "first": "Andrew D.",
                    "initial": "A.D.",
                    "last": "Oxman"
                },
                {
                    "first": "Jelena",
                    "initial": "J.",
                    "last": "Savovi\u0107"
                },
                {
                    "first": "Kenneth F.",
                    "initial": "K.F.",
                    "last": "Schulz"
                },
                {
                    "first": "Laura",
                    "initial": "L.",
                    "last": "Weeks"
                },
                {
                    "first": "Jonathan A.C.",
                    "initial": "J.A.C.",
                    "last": "Sterne"
                }
            ],
            "doi": "10.1136/bmj.d5928",
            "issn": "09598146",
            "pmid": "22008217",
            "pub_year": 2011,
            "title": "The Cochrane Collaboration's tool for assessing risk of bias in randomised trials",
            "volume": "343"
        },
        "bib13": {
            "authors": [
                {
                    "first": "Bria",
                    "initial": "B.",
                    "last": "Hutton"
                },
                {
                    "first": "Georgi",
                    "initial": "G.",
                    "last": "Salanti"
                },
                {
                    "first": "Deborah M.",
                    "initial": "D.M.",
                    "last": "Caldwell"
                },
                {
                    "first": "Ann",
                    "initial": "A.",
                    "last": "Chaimani"
                },
                {
                    "first": "Christopher H.",
                    "initial": "C.H.",
                    "last": "Schmid"
                },
                {
                    "first": "Chri",
                    "initial": "C.",
                    "last": "Cameron"
                },
                {
                    "first": "John P.A.",
                    "initial": "J.P.A.",
                    "last": "Ioannidis"
                },
                {
                    "first": "Sharo",
                    "initial": "S.",
                    "last": "Straus"
                },
                {
                    "first": "Kristia",
                    "initial": "K.",
                    "last": "Thorlund"
                },
                {
                    "first": "Jeroen P.",
                    "initial": "J.P.",
                    "last": "Jansen"
                },
                {
                    "first": "Cynthi",
                    "initial": "C.",
                    "last": "Mulrow"
                },
                {
                    "first": "Ferra",
                    "initial": "F.",
                    "last": "Catala-Lopez"
                },
                {
                    "first": "Peter C.",
                    "initial": "P.C.",
                    "last": "Gotzsche"
                },
                {
                    "first": "Ka",
                    "initial": "K.",
                    "last": "Dickersin"
                },
                {
                    "first": "Isabell",
                    "initial": "I.",
                    "last": "Boutron"
                },
                {
                    "first": "Douglas G.",
                    "initial": "D.G.",
                    "last": "Altman"
                },
                {
                    "first": "Davi",
                    "initial": "D.",
                    "last": "Moher"
                }
            ],
            "doi": "10.7326/M14-2385",
            "firstpage": "777",
            "issn": "00034819",
            "lastpage": "784",
            "pmid": "26030634",
            "pub_year": 2015,
            "title": "The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations",
            "volume": "162"
        },
        "bib14": {
            "authors": [],
            "doi": "10.1016/S0140-6736(88)92833-4",
            "firstpage": "349",
            "issn": "01406736",
            "lastpage": "360",
            "pmid": "2899772",
            "pub_year": 1988,
            "title": "RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2",
            "volume": "332"
        },
        "bib15": {
            "authors": [
                {
                    "first": "Stefan",
                    "initial": "S.",
                    "last": "Leucht"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Chaimani"
                },
                {
                    "first": "Andrea S.",
                    "initial": "A.S.",
                    "last": "Cipriani"
                },
                {
                    "first": "John M.",
                    "initial": "J.M.",
                    "last": "Davis"
                },
                {
                    "first": "Toshi A.",
                    "initial": "T.A.",
                    "last": "Furukawa"
                },
                {
                    "first": "Georgia",
                    "initial": "G.",
                    "last": "Salanti"
                }
            ],
            "doi": "10.1007/s00406-016-0715-4",
            "firstpage": "477",
            "issn": "09401334",
            "lastpage": "480",
            "pmid": "27435721",
            "pub_year": 2016,
            "title": "Network meta-analyses should be the highest level of evidence in treatment guidelines",
            "volume": "266"
        },
        "bib16": {
            "authors": [
                {
                    "first": "Vincent W.",
                    "initial": "V.W.",
                    "last": "Lin"
                },
                {
                    "first": "Sarah",
                    "initial": "S.",
                    "last": "Ringold"
                },
                {
                    "first": "Emily Beth",
                    "initial": "E.B.",
                    "last": "Devine"
                }
            ],
            "doi": "10.1001/2013.jamadermatol.238",
            "firstpage": "1403",
            "issn": "0003987X",
            "lastpage": "1410",
            "pub_year": 2012,
            "title": "Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: A bayesian network meta-analysis",
            "volume": "148"
        },
        "bib17": {
            "authors": [
                {
                    "first": "T. C.",
                    "initial": "T.C.",
                    "last": "Lucka"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Pathirana"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Sammain"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Bachmann"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Rosumeck"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Erdmann"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Schmitt"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Orawa"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Rzany"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Nast"
                }
            ],
            "doi": "10.1111/j.1468-3083.2012.04492.x",
            "firstpage": "1331",
            "issn": "09269959",
            "lastpage": "1344",
            "pmid": "22404617",
            "pub_year": 2012,
            "title": "Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment",
            "volume": "26"
        },
        "bib18": {
            "authors": [
                {
                    "first": "Edward J.",
                    "initial": "E.J.",
                    "last": "Mills"
                },
                {
                    "first": "Kristian",
                    "initial": "K.",
                    "last": "Thorlund"
                },
                {
                    "first": "John P.A.",
                    "initial": "J.P.A.",
                    "last": "Ioannidis"
                }
            ],
            "doi": "10.1136/bmj.f2914",
            "issn": "17561833",
            "pmid": "23674332",
            "pub_year": 2013,
            "title": "Demystifying trial networks and network meta-analysis.",
            "volume": "346"
        },
        "bib19": {
            "authors": [
                {
                    "first": "Alexander",
                    "initial": "A.",
                    "last": "Nast"
                },
                {
                    "first": "Anja",
                    "initial": "A.",
                    "last": "Jacobs"
                },
                {
                    "first": "Stefanie",
                    "initial": "S.",
                    "last": "Rosumeck"
                },
                {
                    "first": "Ricardo N.",
                    "initial": "R.N.",
                    "last": "Werner"
                }
            ],
            "doi": "10.1038/jid.2015.206",
            "firstpage": "2641",
            "issn": "0022202X",
            "lastpage": "2648",
            "pmid": "26046458",
            "pub_year": 2015,
            "title": "Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis",
            "volume": "135"
        },
        "bib2": {
            "authors": [
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Barker"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Hoffmann"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Wozel"
                },
                {
                    "first": "J. P.",
                    "initial": "J.P.",
                    "last": "Ortonne"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Zheng"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Van Hoogstraten"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Reich"
                }
            ],
            "doi": "10.1111/j.1365-2133.2011.10615.x",
            "firstpage": "1109",
            "issn": "00070963",
            "lastpage": "1117",
            "pmid": "21910713",
            "pub_year": 2011,
            "title": "Efficacy and safety of infliximab vs. Methotrexate in patients with moderate-to-severe plaque psoriasis: Results of an open-label, active-controlled, randomized trial (RESTORE1)",
            "volume": "165"
        },
        "bib20": {
            "authors": [
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Reich"
                },
                {
                    "first": "A. D.",
                    "initial": "A.D.",
                    "last": "Burden"
                },
                {
                    "first": "J. N.",
                    "initial": "J.N.",
                    "last": "Eaton"
                },
                {
                    "first": "N. S.",
                    "initial": "N.S.",
                    "last": "Hawkins"
                }
            ],
            "doi": "10.1111/j.1365-2133.2011.10583.x",
            "firstpage": "179",
            "issn": "00070963",
            "lastpage": "188",
            "pmid": "21910698",
            "pub_year": 2012,
            "title": "Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials",
            "volume": "166"
        },
        "bib21": {
            "authors": [
                {
                    "first": "Georgia",
                    "initial": "G.",
                    "last": "Salanti"
                },
                {
                    "first": "A. E.",
                    "initial": "A.E.",
                    "last": "Ades"
                },
                {
                    "first": "John P.A.",
                    "initial": "J.P.A.",
                    "last": "Ioannidis"
                }
            ],
            "doi": "10.1016/j.jclinepi.2010.03.016",
            "firstpage": "163",
            "issn": "08954356",
            "lastpage": "171",
            "pmid": "20688472",
            "pub_year": 2011,
            "title": "Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial",
            "volume": "64"
        },
        "bib22": {
            "authors": [
                {
                    "first": "J. H.",
                    "initial": "J.H.",
                    "last": "Saurat"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Stingl"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Dubertret"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Papp"
                },
                {
                    "first": "R. G.",
                    "initial": "R.G.",
                    "last": "Langley"
                },
                {
                    "first": "J. P.",
                    "initial": "J.P.",
                    "last": "Ortonne"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Unnebrink"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Kaul"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Camez"
                }
            ],
            "doi": "10.1111/j.1365-2133.2007.08315.x",
            "firstpage": "558",
            "issn": "00070963",
            "lastpage": "566",
            "pmid": "18047523",
            "pub_year": 2008,
            "title": "Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)",
            "volume": "158"
        },
        "bib23": {
            "authors": [
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Schmitt"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Rosumeck"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Thomaschewski"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Sporbeck"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Haufe"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Nast"
                }
            ],
            "doi": "10.1111/bjd.12663",
            "firstpage": "274",
            "issn": "00070963",
            "lastpage": "303",
            "pmid": "24131260",
            "pub_year": 2014,
            "title": "Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials",
            "volume": "170"
        },
        "bib24": {
            "authors": [
                {
                    "first": "J. E.",
                    "initial": "J.E.",
                    "last": "Signorovitch"
                },
                {
                    "first": "K. A.",
                    "initial": "K.A.",
                    "last": "Betts"
                },
                {
                    "first": "Y. S.",
                    "initial": "Y.S.",
                    "last": "Yan"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Lereun"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Sundaram"
                },
                {
                    "first": "E. Q.",
                    "initial": "E.Q.",
                    "last": "Wu"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Mulani"
                }
            ],
            "doi": "10.1111/bjd.13437",
            "firstpage": "504",
            "issn": "00070963",
            "lastpage": "512",
            "pmid": "25288183",
            "pub_year": 2015,
            "title": "Comparative efficacy of biological treatments for moderate-to-severe psoriasis: A network meta-analysis adjusting for cross-trial differences in reference arm response",
            "volume": "172"
        },
        "bib25": {
            "authors": [
                {
                    "first": "Jasvinder A.",
                    "initial": "J.A.",
                    "last": "Singh"
                },
                {
                    "first": "Chris",
                    "initial": "C.",
                    "last": "Cameron"
                },
                {
                    "first": "Shahrzad",
                    "initial": "S.",
                    "last": "Noorbaloochi"
                },
                {
                    "first": "Tyler",
                    "initial": "T.",
                    "last": "Cullis"
                },
                {
                    "first": "Matthew",
                    "initial": "M.",
                    "last": "Tucker"
                },
                {
                    "first": "Robin",
                    "initial": "R.",
                    "last": "Christensen"
                },
                {
                    "first": "Elizabeth Tanjong",
                    "initial": "E.T.",
                    "last": "Ghogomu"
                },
                {
                    "first": "Doug",
                    "initial": "D.",
                    "last": "Coyle"
                },
                {
                    "first": "Tammy",
                    "initial": "T.",
                    "last": "Clifford"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Tugwell"
                },
                {
                    "first": "George A.",
                    "initial": "G.A.",
                    "last": "Wells"
                }
            ],
            "doi": "10.1016/S0140-6736(14)61704-9",
            "firstpage": "258",
            "issn": "01406736",
            "lastpage": "265",
            "pmid": "25975452",
            "pub_year": 2015,
            "title": "Risk of serious infection in biological treatment of patients with rheumatoid arthritis: A systematic review and meta-analysis",
            "volume": "386"
        },
        "bib26": null,
        "bib27": {
            "authors": [
                {
                    "first": "Ian R.",
                    "initial": "I.R.",
                    "last": "White"
                }
            ],
            "firstpage": "255",
            "issn": "1536867X",
            "lastpage": "270",
            "pub_year": 2011,
            "title": "Multivariate random-effects meta-regression: Updates to mvmeta",
            "volume": "11"
        },
        "bib28": {
            "authors": [
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Woolacott"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Hawkins"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Mason"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Kainth"
                },
                {
                    "first": "Z.",
                    "initial": "Z.",
                    "last": "Khadjesari"
                },
                {
                    "first": "Y. Bravo",
                    "initial": "Y.B.",
                    "last": "Vergel"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Misso"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Light"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Chalmers"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Sculpher"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Riemsma"
                }
            ],
            "doi": "10.3310/hta10460",
            "issn": "13665278",
            "pmid": "17083854",
            "pub_year": 2006,
            "title": "Etanercept and efalizumab for the treatment of psoriasis: A systematic review",
            "volume": "10"
        },
        "bib3": {
            "authors": [
                {
                    "first": "M. K.A.",
                    "initial": "M.K.A.",
                    "last": "Basra"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Salek"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Camilleri"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Sturkey"
                },
                {
                    "first": "A. Y.",
                    "initial": "A.Y.",
                    "last": "Finlay"
                }
            ],
            "doi": "10.1159/000365390",
            "firstpage": "27",
            "issn": "10188665",
            "lastpage": "33",
            "pmid": "25613671",
            "pub_year": 2015,
            "title": "Determining the minimal clinically important difference and responsiveness of the dermatology life quality index (DLQI): Further data",
            "volume": "230"
        },
        "bib4": {
            "authors": [
                {
                    "first": "Heiner C.",
                    "initial": "H.C.",
                    "last": "Bucher"
                },
                {
                    "first": "Gordon H.",
                    "initial": "G.H.",
                    "last": "Guyatt"
                },
                {
                    "first": "Lauren E.",
                    "initial": "L.E.",
                    "last": "Griffith"
                },
                {
                    "first": "Stephen D.",
                    "initial": "S.D.",
                    "last": "Walter"
                }
            ],
            "doi": "10.1016/S0895-4356(97)00049-8",
            "firstpage": "683",
            "issn": "08954356",
            "lastpage": "691",
            "pmid": "9250266",
            "pub_year": 1997,
            "title": "The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials",
            "volume": "50"
        },
        "bib5": {
            "authors": [
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Chaimani"
                },
                {
                    "first": "Julian P.T.",
                    "initial": "J.P.T.",
                    "last": "Higgins"
                },
                {
                    "first": "Dimitris",
                    "initial": "D.",
                    "last": "Mavridis"
                },
                {
                    "first": "Panagiota",
                    "initial": "P.",
                    "last": "Spyridonos"
                },
                {
                    "first": "Georgia",
                    "initial": "G.",
                    "last": "Salanti"
                }
            ],
            "doi": "10.1371/journal.pone.0076654",
            "issn": "19326203",
            "pmid": "24098547",
            "pub_year": 2013,
            "title": "Graphical Tools for Network Meta-Analysis in STATA",
            "volume": "8"
        },
        "bib6": {
            "authors": [
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Chaimani"
                },
                {
                    "first": "Dimitris",
                    "initial": "D.",
                    "last": "Mavridis"
                },
                {
                    "first": "Georgia",
                    "initial": "G.",
                    "last": "Salanti"
                }
            ],
            "doi": "10.1136/eb-2014-101967",
            "firstpage": "111",
            "issn": "13620347",
            "lastpage": "116",
            "pmid": "25288685",
            "pub_year": 2014,
            "title": "A hands-on practical tutorial on performing meta-analysis with Stata",
            "volume": "17"
        },
        "bib7": {
            "authors": [
                {
                    "first": "A. C.Q.",
                    "initial": "A.C.Q.",
                    "last": "de Vries"
                },
                {
                    "first": "H. B.",
                    "initial": "H.B.",
                    "last": "Thio"
                },
                {
                    "first": "W. J.A.",
                    "initial": "W.J.A.",
                    "last": "de Kort"
                },
                {
                    "first": "B. C.",
                    "initial": "B.C.",
                    "last": "Opmeer"
                },
                {
                    "first": "H. M.",
                    "initial": "H.M.",
                    "last": "van der Stok"
                },
                {
                    "first": "E. M.G.J.",
                    "initial": "E.M.G.J.",
                    "last": "de Jong"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Horvath"
                },
                {
                    "first": "J. J.V.",
                    "initial": "J.J.V.",
                    "last": "Busschbach"
                },
                {
                    "first": "T. E.C.",
                    "initial": "T.E.C.",
                    "last": "Nijsten"
                },
                {
                    "first": "Ph I.",
                    "initial": "P.I.",
                    "last": "Spuls"
                }
            ],
            "doi": "10.1111/bjd.14867",
            "firstpage": "624",
            "issn": "00070963",
            "lastpage": "633",
            "pmid": "27416891",
            "pub_year": 2017,
            "title": "A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study",
            "volume": "176"
        },
        "bib8": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Galv\u00e1n-Banqueri"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Mar\u00edn Gil"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Santos Ramos"
                },
                {
                    "first": "F. J.",
                    "initial": "F.J.",
                    "last": "Bautista Paloma"
                }
            ],
            "doi": "10.1111/jcpt.12044",
            "firstpage": "121",
            "issn": "02694727",
            "lastpage": "130",
            "pmid": "23442134",
            "pub_year": 2013,
            "title": "Biological treatments for moderate-to-severe psoriasis: Indirect comparison",
            "volume": "38"
        },
        "bib9": {
            "authors": [
                {
                    "first": "Ignacio",
                    "initial": "I.",
                    "last": "Garcia-Doval"
                },
                {
                    "first": "Gregorio",
                    "initial": "G.",
                    "last": "Carretero"
                },
                {
                    "first": "Francisco",
                    "initial": "F.",
                    "last": "Vanaclocha"
                },
                {
                    "first": "Carlos",
                    "initial": "C.",
                    "last": "Ferrandiz"
                },
                {
                    "first": "Esteban",
                    "initial": "E.",
                    "last": "Daud\u00e9n"
                },
                {
                    "first": "Jose Luis",
                    "initial": "J.L.",
                    "last": "S\u00e1nchez-Carazo"
                },
                {
                    "first": "Merc\u00e9",
                    "initial": "M.",
                    "last": "Alsina"
                },
                {
                    "first": "Enrique",
                    "initial": "E.",
                    "last": "Herrera-Ceballos"
                },
                {
                    "first": "Francisco Jos\u00e9",
                    "initial": "F.J.",
                    "last": "G\u00f3mez-Garc\u00eda"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Ferr\u00e1n"
                },
                {
                    "first": "Jose Luis",
                    "initial": "J.L.",
                    "last": "L\u00f3pez-Estebaranz"
                },
                {
                    "first": "Jose Manuel",
                    "initial": "J.M.",
                    "last": "Hernanz"
                },
                {
                    "first": "Isabel",
                    "initial": "I.",
                    "last": "Belinch\u00f3n-Romero"
                },
                {
                    "first": "Jaime",
                    "initial": "J.",
                    "last": "Vilar-Alejo"
                },
                {
                    "first": "Raquel",
                    "initial": "R.",
                    "last": "Rivera"
                },
                {
                    "first": "Jose Manuel",
                    "initial": "J.M.",
                    "last": "Carrascosa"
                },
                {
                    "first": "Cristina",
                    "initial": "C.",
                    "last": "Carazo"
                }
            ],
            "doi": "10.1001/archdermatol.2011.2768",
            "firstpage": "463",
            "issn": "0003987X",
            "lastpage": "470",
            "pmid": "22508869",
            "pub_year": 2012,
            "title": "Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: Patients ineligible vs eligible for randomized controlled trials",
            "volume": "148"
        }
    },
    "body_text": [
        {
            "endOffset": 34159,
            "parents": [],
            "secId": "sec3",
            "sentence": "There is evidence of small study effects favoring older treatments with respect to the efficacy outcomes of clear/nearly clear and PASI 75.",
            "startOffset": 34020,
            "title": "Discussion"
        },
        {
            "endOffset": 37567,
            "parents": [],
            "secId": "sec4",
            "sentence": "The review protocol was registered on the PROSPERO international prospective register of systematic reviews (2015:CRD42015017538) (Supplementary Table S2).",
            "startOffset": 37412,
            "title": "Materials and Methods"
        },
        {
            "endOffset": 38991,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.1",
            "sentence": "All studies reported in a language other than English were excluded.",
            "startOffset": 38923,
            "title": "Search and study selection"
        },
        {
            "endOffset": 42734,
            "parents": [],
            "secId": "sec6",
            "sentence": "CMO, ES, LSE, MFMM, RP, VV, ZKJ-L, and ZZNY have no conflicts of interest to declare.",
            "startOffset": 42649,
            "title": "Conflict of Interest"
        },
        {
            "endOffset": 23379,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.3",
            "sentence": "The risk of bias varied between individual studies, ranging from low to high (Supplementary Figures S1 and S2 online).",
            "startOffset": 23261,
            "title": "Risk of bias"
        },
        {
            "endOffset": 40279,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.2",
            "sentence": "Cumulative ranking probability plots were used to represent the ranking probabilities of the various treatments with a visual estimation of their uncertainty.",
            "startOffset": 40121,
            "title": "Data analysis and quality assessment of evidence"
        },
        {
            "endOffset": 34701,
            "parents": [],
            "refoffsets": {
                "bib5": {
                    "endOffset": 34699,
                    "startOffset": 34678
                }
            },
            "secId": "sec3",
            "sentence": "Consistency refers to the level of agreement between direct and indirect sources of evidence and transitivity refers to the assumption that available treatment comparisons do not differ with respect to the distribution of effect modifiers (Chaimani et al., 2013).",
            "startOffset": 34438,
            "title": "Discussion"
        },
        {
            "endOffset": 26918,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.6",
            "sentence": "Infliximab and ixekizumab formed another cluster, characterized by high efficacy with poorer tolerability.",
            "startOffset": 26812,
            "title": "Joint rankings of efficacy and tolerability"
        },
        {
            "endOffset": 35063,
            "parents": [],
            "secId": "sec3",
            "sentence": "Varying levels of previous biologic use among participants in the included studies may be important.",
            "startOffset": 34963,
            "title": "Discussion"
        },
        {
            "endOffset": 26531,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.6",
            "sentence": "Placebo formed its own group, characterized by low efficacy.",
            "startOffset": 26471,
            "title": "Joint rankings of efficacy and tolerability"
        },
        {
            "endOffset": 26811,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.6",
            "sentence": "Adalimumab, secukinumab, and ustekinumab formed one cluster, characterized by high efficacy and tolerability.",
            "startOffset": 26702,
            "title": "Joint rankings of efficacy and tolerability"
        },
        {
            "endOffset": 24792,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.4",
            "sentence": "In terms of clear/nearly clear and PASI 75, ixekizumab performed best (surface under the cumulative ranking curve [SUCRA] 99.4) and placebo performed worst (SUCRA 0.0) (see Relative treatment rankings, Table 2).",
            "startOffset": 24581,
            "title": "Efficacy of biologic treatments at 12 to 16 weeks"
        },
        {
            "endOffset": 40120,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.2",
            "sentence": "Predictive intervals were calculated to provide an interval within which the estimate of a future study would be expected.",
            "startOffset": 39998,
            "title": "Data analysis and quality assessment of evidence"
        },
        {
            "endOffset": 23498,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.3",
            "sentence": "A total of 35 of 41 (85%) RCTs had a low risk of selection bias and 37 of 41 (90%) had a low risk of performance bias.",
            "startOffset": 23380,
            "title": "Risk of bias"
        },
        {
            "endOffset": 23955,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.3",
            "sentence": "Regarding publication bias, comparison-adjusted funnel plots suggested asymmetry between small studies for the outcomes of clear/nearly clear and PASI 75 at 12 to 16 weeks in relation to newer versus established treatments.",
            "startOffset": 23732,
            "title": "Risk of bias"
        },
        {
            "endOffset": 32959,
            "parents": [],
            "secId": "sec3",
            "sentence": "The rankings are likely to be robust as the rankings obtained from the predictive probabilities, taking into account uncertainty, are consistent with rankings from the estimated probabilities.",
            "startOffset": 32767,
            "title": "Discussion"
        },
        {
            "endOffset": 37073,
            "parents": [],
            "secId": "sec3",
            "sentence": "Improved efficacy of biologics may be at the expense of tolerability, and this tradeoff should be considered in the development and evaluation of new biologic treatments for psoriasis.",
            "startOffset": 36889,
            "title": "Discussion"
        },
        {
            "endOffset": 28182,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.7",
            "sentence": "There was statistically significant evidence of inconsistency for the outcome of PASI 75 (\u03c72(9) = 22.89, P = 0.006).",
            "startOffset": 28066,
            "title": "Inconsistency"
        },
        {
            "endOffset": 33247,
            "parents": [],
            "refoffsets": {
                "bib9": {
                    "endOffset": 33245,
                    "startOffset": 33220
                }
            },
            "secId": "sec3",
            "sentence": "These populations may be importantly different from patients treated in day-to-day clinical practice (Garcia-Doval et al., 2012).",
            "startOffset": 33118,
            "title": "Discussion"
        },
        {
            "endOffset": 35768,
            "parents": [],
            "secId": "sec3",
            "sentence": "It may also overestimate the effect of methotrexate compared with studies where patients have previously received methotrexate.",
            "startOffset": 35641,
            "title": "Discussion"
        },
        {
            "endOffset": 23249,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.2",
            "sentence": "Fewer direct comparisons were available for mean change in dermatology life quality index (DLQI) (see Figure 2b).",
            "startOffset": 23136,
            "title": "Network structure"
        },
        {
            "endOffset": 30495,
            "parents": [],
            "secId": "sec3",
            "sentence": "Ixekizumab, while the most efficacious treatment in terms of clear/nearly clear, was relatively less well tolerated than placebo, adalimumab, or secukinumab.",
            "startOffset": 30338,
            "title": "Discussion"
        },
        {
            "endOffset": 40921,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "refoffsets": {
                "bib5": {
                    "endOffset": 40919,
                    "startOffset": 40898
                }
            },
            "secId": "sec4.2",
            "sentence": "Cluster analysis is an exploratory data mining technique for grouping objects based on their features so that the degree of association is high between members of the same group and low between members of different groups (Chaimani et al., 2013).",
            "startOffset": 40675,
            "title": "Data analysis and quality assessment of evidence"
        },
        {
            "endOffset": 28065,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.7",
            "sentence": "Statistically significant loop inconsistency was identified in the loop containing etanercept, ustekinumab, and secukinumab.",
            "startOffset": 27941,
            "title": "Inconsistency"
        },
        {
            "endOffset": 32565,
            "parents": [],
            "secId": "sec3",
            "sentence": "Our review incorporates a wider number of studies as well as the new anti-IL-17A biologic, ixekizumab, and methotrexate as an important comparator.",
            "startOffset": 32418,
            "title": "Discussion"
        },
        {
            "endOffset": 19985,
            "parents": [],
            "secId": "sec1",
            "sentence": "There are several advantages of this approach, namely, that the indirect evidence can fill gaps in the evidence and all comparisons can be considered simultaneously.",
            "startOffset": 19820,
            "title": "Introduction"
        },
        {
            "endOffset": 36888,
            "parents": [],
            "secId": "sec3",
            "sentence": "Clinically, the use of hierarchical cluster analysis in conjunction with NMA provides an objective simultaneous assessment of multiple outcomes of efficacy and tolerability that allows discrimination.",
            "startOffset": 36688,
            "title": "Discussion"
        },
        {
            "endOffset": 21393,
            "parents": [],
            "secId": "sec1",
            "sentence": "We performed an NMA and hierarchical cluster analysis to rank the biologic therapies in terms of a combination of both efficacy and tolerability in an objective way.",
            "startOffset": 21228,
            "title": "Introduction"
        },
        {
            "endOffset": 22400,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.1",
            "sentence": "Excluded studies are given in Supplementary Table S2 (online).",
            "startOffset": 22338,
            "title": "Study selection and characteristics"
        },
        {
            "endOffset": 38922,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.1",
            "sentence": "The systematic literature search was conducted in PubMed, MEDLINE, Embase, and Cochrane databases; see Supplementary Appendix S3 (Search terms and strategy).",
            "startOffset": 38765,
            "title": "Search and study selection"
        },
        {
            "endOffset": 26701,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.6",
            "sentence": "Three distinct clusters of treatments were identified when considering efficacy (clear/near clear) and tolerability (withdrawal due to adverse events) jointly (Figure 3).",
            "startOffset": 26531,
            "title": "Joint rankings of efficacy and tolerability"
        },
        {
            "endOffset": 20720,
            "parents": [],
            "secId": "sec1",
            "sentence": "Tolerability is not directly measured in clinical trials; however, in a clinical trial setting, it can be inferred by patients\u2019 willingness to continue on treatment.",
            "startOffset": 20555,
            "title": "Introduction"
        },
        {
            "endOffset": 33647,
            "parents": [],
            "secId": "sec3",
            "sentence": "Furthermore, outcomes at 3\u20134 months represent a relatively short-term timeframe in this chronic condition that can persist for many years.",
            "startOffset": 33509,
            "title": "Discussion"
        },
        {
            "endOffset": 42648,
            "parents": [],
            "secId": "sec6",
            "sentence": "RBW has acted as a consultant and/or speaker and/or received research grants for Abbvie, Amgen, Almirall, Celgene, Boehringer, Eli Lillly, Pfizer, Leo, Novartis, Xenoport, and Janssen.",
            "startOffset": 42464,
            "title": "Conflict of Interest"
        },
        {
            "endOffset": 39844,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "refoffsets": {
                "bib21": {
                    "endOffset": 39842,
                    "startOffset": 39801
                },
                "bib4": {
                    "endOffset": 39842,
                    "startOffset": 39801
                }
            },
            "secId": "sec4.2",
            "sentence": "NMA increases the precision in the estimates and produces a relative ranking of all treatments for the studied outcome (Bucher et al., 1997; Salanti et al., 2011).",
            "startOffset": 39681,
            "title": "Data analysis and quality assessment of evidence"
        },
        {
            "endOffset": 34962,
            "parents": [],
            "secId": "sec3",
            "sentence": "Transitivity cannot directly be tested but would be expected to hold as the characteristics of the patients in the studies are broadly similar given the requirements for patients to have moderate-severe psoriasis and to have received previous systemic therapy.",
            "startOffset": 34702,
            "title": "Discussion"
        },
        {
            "endOffset": 37673,
            "parents": [],
            "secId": "sec4",
            "sentence": "A more detailed description of the methods is given in Supplementary Appendix S2 (Supplementary methods).",
            "startOffset": 37568,
            "title": "Materials and Methods"
        },
        {
            "endOffset": 20950,
            "parents": [],
            "refoffsets": {
                "bib10": {
                    "endOffset": 20760,
                    "startOffset": 20735
                }
            },
            "secId": "sec1",
            "sentence": "Only one NMA (Gomez-Garcia et al., 2017) has investigated both efficacy and the risk of adverse events of biologics for psoriasis, and thus far no study has investigated the efficacy and tolerability of treatments in combination.",
            "startOffset": 20721,
            "title": "Introduction"
        },
        {
            "endOffset": 30123,
            "parents": [],
            "refoffsets": {
                "bib14": {
                    "endOffset": 30121,
                    "startOffset": 30109
                }
            },
            "secId": "sec3",
            "sentence": "These numbers needed to treat are significant compared with, for example, the numbers needed to treat of 42 for aspirin in prevention of death in acute myocardial infarction (ISIS-2, 1988).",
            "startOffset": 29934,
            "title": "Discussion"
        },
        {
            "endOffset": 20139,
            "parents": [],
            "refoffsets": {
                "bib15": {
                    "endOffset": 20137,
                    "startOffset": 20118
                }
            },
            "secId": "sec1",
            "sentence": "In addition, the pooled estimates can provide greater statistical power and precision than can be obtained from individual studies (Leucht et al., 2016).",
            "startOffset": 19986,
            "title": "Introduction"
        },
        {
            "endOffset": 25612,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.5",
            "sentence": "There were statistically significant increased odds of withdrawal due to adverse events with infliximab or ixekizumab compared with placebo (Supplementary Figure S6 online).",
            "startOffset": 25439,
            "title": "Tolerability of biologic treatments at 12 to 16 weeks"
        },
        {
            "endOffset": 40539,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.2",
            "sentence": "The larger the SUCRA value, the better the rank.",
            "startOffset": 40491,
            "title": "Data analysis and quality assessment of evidence"
        },
        {
            "endOffset": 28823,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.8",
            "sentence": "A predefined subgroup analysis was performed using studies comparing only licensed biologic doses (Supplementary Figures S25\u2013S27 online).",
            "startOffset": 28686,
            "title": "Subgroup analysis"
        },
        {
            "endOffset": 38101,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.1",
            "sentence": "The comparison arm could consist of any of the listed biologic therapies above, placebo or methotrexate.",
            "startOffset": 37997,
            "title": "Search and study selection"
        },
        {
            "endOffset": 25870,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.5",
            "sentence": "Ixekizumab was associated with higher odds of withdrawal compared with adalimumab, ustekinumab, and secukinumab (Table 1).",
            "startOffset": 25748,
            "title": "Tolerability of biologic treatments at 12 to 16 weeks"
        },
        {
            "endOffset": 37996,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.1",
            "sentence": "RCTs were considered for inclusion if the intervention consisted of one or more of the following: adalimumab, etanercept, infliximab, ixekizumab, ustekinumab, and secukinumab.",
            "startOffset": 37821,
            "title": "Search and study selection"
        },
        {
            "endOffset": 30338,
            "parents": [],
            "refoffsets": {
                "bib3": {
                    "endOffset": 30326,
                    "startOffset": 30308
                }
            },
            "secId": "sec3",
            "sentence": "Apart from placebo comparisons, the absolute differences in mean change in DLQI were small and below the conventionally clinically significant difference of 4 units on the DLQI scale (Basra et al., 2015) (Table 1).",
            "startOffset": 30124,
            "title": "Discussion"
        },
        {
            "endOffset": 42463,
            "parents": [],
            "secId": "sec6",
            "sentence": "CHS has received departmental research funding from Abbvie, Pfizer, Novartis, GSK, Roche, Regeneron, and Janssen.",
            "startOffset": 42350,
            "title": "Conflict of Interest"
        },
        {
            "endOffset": 31697,
            "parents": [],
            "secId": "sec3",
            "sentence": "When the data on licensed doses only were analyzed in the NMA, the position of ixekizumab remained unchanged in terms of efficacy; however, its ranking in terms of withdrawal due to adverse events improved from 7th to 6th.",
            "startOffset": 31475,
            "title": "Discussion"
        },
        {
            "endOffset": 38711,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.1",
            "sentence": "Outcomes were extracted at 3\u20134 months, 1 year, and 3 years.",
            "startOffset": 38652,
            "title": "Search and study selection"
        },
        {
            "endOffset": 41633,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "refoffsets": {
                "bib5": {
                    "endOffset": 41631,
                    "startOffset": 41610
                }
            },
            "secId": "sec4.2",
            "sentence": "Inconsistency was also tested formally using an overall chi-squared test of inconsistency and through loop-specific inconsistency plots and calculation of an inconsistency factor (Chaimani et al., 2013).",
            "startOffset": 41430,
            "title": "Data analysis and quality assessment of evidence"
        },
        {
            "endOffset": 22242,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.1",
            "sentence": "All trials involved patients with moderate-severe chronic plaque psoriasis; 29 of 41 (71%) studies included patients with a psoriasis area and severity index (PASI) \u2265 12, 7 of 41 (17%) with a PASI \u2265 10, and 5 of 41 (12%) with \u201cmoderate to severe\u201d disease, not otherwise specified.",
            "startOffset": 21962,
            "title": "Study selection and characteristics"
        },
        {
            "endOffset": 36687,
            "parents": [],
            "secId": "sec3",
            "sentence": "These results suggest that, ideally, direct head-to-head comparisons should be made with adalimumab (where there is currently a complete absence of head-to-head studies), ixekizumab, secukinumab, or ustekinumab.",
            "startOffset": 36476,
            "title": "Discussion"
        },
        {
            "endOffset": 25000,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.4",
            "sentence": "The rankings calculated using predictive probabilities were consistent with the estimated probabilities.",
            "startOffset": 24896,
            "title": "Efficacy of biologic treatments at 12 to 16 weeks"
        },
        {
            "endOffset": 18693,
            "parents": [],
            "refoffsets": {
                "bib17": {
                    "endOffset": 18605,
                    "startOffset": 18516
                },
                "bib19": {
                    "endOffset": 18605,
                    "startOffset": 18516
                },
                "bib23": {
                    "endOffset": 18605,
                    "startOffset": 18516
                },
                "bib8": {
                    "endOffset": 18605,
                    "startOffset": 18516
                }
            },
            "secId": "sec1",
            "sentence": "Currently, a total of six distinct biologic therapies are licensed for use in Europe and the USA: adalimumab, etanercept, infliximab, ixekizumab, secukinumab, and ustekinumab, all of which perform significantly better than placebo (Galvan-Banqueri et al., 2013; Lucka et al., 2012; Nast et al., 2015; Schmitt et al., 2014), thus providing real choice in terms of treatment options for patients with psoriasis.",
            "startOffset": 18284,
            "title": "Introduction"
        },
        {
            "endOffset": 32417,
            "parents": [],
            "refoffsets": {
                "bib10": {
                    "endOffset": 32305,
                    "startOffset": 32279
                }
            },
            "secId": "sec3",
            "sentence": "For example, the NMA by Gomez-Garcia et al. (2017) suggested that infliximab, secukinumab, and ustekinumab were the most efficacious treatments in the short term.",
            "startOffset": 32255,
            "title": "Discussion"
        },
        {
            "endOffset": 32254,
            "parents": [],
            "secId": "sec3",
            "sentence": "These findings are broadly consistent with previously published NMAs on biologics for psoriasis.",
            "startOffset": 32158,
            "title": "Discussion"
        },
        {
            "endOffset": 24895,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.4",
            "sentence": "Secukinumab performed best (SUCRA 84.3) and placebo worst (SUCRA 0.1) in terms of mean change in DLQI.",
            "startOffset": 24793,
            "title": "Efficacy of biologic treatments at 12 to 16 weeks"
        },
        {
            "endOffset": 42104,
            "parents": [],
            "secId": "sec5",
            "sentence": "Zarif K. Jabbar-Lopez: http://orcid.org/0000-0003-4127-8263",
            "startOffset": 42045,
            "title": "ORCIDs"
        },
        {
            "endOffset": 42349,
            "parents": [],
            "secId": "sec6",
            "sentence": "ADB consults and lectures for Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Celgene, Janssen, and Boehringer Ingelheim.",
            "startOffset": 42232,
            "title": "Conflict of Interest"
        },
        {
            "endOffset": 19484,
            "parents": [],
            "secId": "sec1",
            "sentence": "We therefore wished to summarize the available data on biologic therapies for psoriasis in a meaningful way that can inform decision making by patients and clinicians.",
            "startOffset": 19317,
            "title": "Introduction"
        },
        {
            "endOffset": 21683,
            "parents": [],
            "secId": "sec1",
            "sentence": "This work will also inform the development work for the updated British Association of Dermatologists\u2019 guidelines for the use of biologic therapies in psoriasis.",
            "startOffset": 21522,
            "title": "Introduction"
        },
        {
            "endOffset": 42212,
            "parents": [],
            "secId": "sec5",
            "sentence": "Zenas Z.N. Yiu: http://orcid.org/0000-0002-1831-074X",
            "startOffset": 42160,
            "title": "ORCIDs"
        },
        {
            "endOffset": 38407,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.1",
            "sentence": "The \u201ccritical\u201d outcomes were those of efficacy: clear/nearly clear (minimal residual activity/PASI > 90/0 or 1 on physician\u2019s global assessment) and mean change in DLQI.",
            "startOffset": 38238,
            "title": "Search and study selection"
        },
        {
            "endOffset": 20367,
            "parents": [],
            "refoffsets": {
                "bib1": {
                    "endOffset": 20286,
                    "startOffset": 20149
                },
                "bib10": {
                    "endOffset": 20286,
                    "startOffset": 20149
                },
                "bib16": {
                    "endOffset": 20286,
                    "startOffset": 20149
                },
                "bib20": {
                    "endOffset": 20286,
                    "startOffset": 20149
                },
                "bib24": {
                    "endOffset": 20286,
                    "startOffset": 20149
                },
                "bib28": {
                    "endOffset": 20286,
                    "startOffset": 20149
                }
            },
            "secId": "sec1",
            "sentence": "Six NMAs (Bansback et al., 2009; Gomez-Garcia et al., 2017; Lin et al., 2012; Reich et al., 2012; Signorovitch et al., 2015; Woolacott et al., 2006) have been published examining the relative efficacy of biologics for psoriasis.",
            "startOffset": 20139,
            "title": "Introduction"
        },
        {
            "endOffset": 24580,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.4",
            "sentence": "The rankograms in Supplementary Figures S11\u2013S13 (online) show the cumulative probabilities (estimated and predictive) for clear/nearly clear, PASI 75, and mean change in DLQI.",
            "startOffset": 24405,
            "title": "Efficacy of biologic treatments at 12 to 16 weeks"
        },
        {
            "endOffset": 41986,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "refoffsets": {
                "bib5": {
                    "endOffset": 41984,
                    "startOffset": 41963
                }
            },
            "secId": "sec4.2",
            "sentence": "Publication bias was assessed with the aid of comparison-adjusted funnel plots, which show the difference between each study\u2019s estimate and the direct summary effect for the respective comparison in terms of newer versus older treatments (Chaimani et al., 2013).",
            "startOffset": 41724,
            "title": "Data analysis and quality assessment of evidence"
        },
        {
            "endOffset": 33117,
            "parents": [],
            "secId": "sec3",
            "sentence": "In particular, the generalizability is limited to the populations included in the RCTs.",
            "startOffset": 33030,
            "title": "Discussion"
        },
        {
            "endOffset": 38237,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.1",
            "sentence": "Outcomes of interest were decided through simple majority voting by the guideline development group, including patient representatives.",
            "startOffset": 38102,
            "title": "Search and study selection"
        },
        {
            "endOffset": 41723,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.2",
            "sentence": "Additional subgroup analysis was performed restricted to data on licensed biologic doses.",
            "startOffset": 41634,
            "title": "Data analysis and quality assessment of evidence"
        },
        {
            "endOffset": 26470,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.6",
            "sentence": "Etanercept and methotrexate formed a separate group that was less efficacious in terms of both outcomes.",
            "startOffset": 26366,
            "title": "Joint rankings of efficacy and tolerability"
        },
        {
            "endOffset": 26237,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.6",
            "sentence": "Using hierarchical clustering, three distinct clusters of treatments were identified with respect to efficacy measured by clear/nearly clear and mean change in DLQI jointly (Supplementary Figure S16 online).",
            "startOffset": 26030,
            "title": "Joint rankings of efficacy and tolerability"
        },
        {
            "endOffset": 31031,
            "parents": [],
            "secId": "sec3",
            "sentence": "A possibility is that dose optimization with respect to efficacy may be at the expense of tolerability.",
            "startOffset": 30928,
            "title": "Discussion"
        },
        {
            "endOffset": 31996,
            "parents": [],
            "secId": "sec3",
            "sentence": "Given this uncertainty, the data on tolerability should be interpreted cautiously.",
            "startOffset": 31914,
            "title": "Discussion"
        },
        {
            "endOffset": 33508,
            "parents": [],
            "secId": "sec3",
            "sentence": "An individual participant NMA would be well placed to explore this and other potential sources of heterogeneity.",
            "startOffset": 33396,
            "title": "Discussion"
        },
        {
            "endOffset": 31474,
            "parents": [],
            "secId": "sec3",
            "sentence": "The ixekizumab studies included a range of dosing regimens; however, all were equivalent to or below the licensed dose, apart from one small group (n = 28) in the dose-finding study who received a cumulative dose higher than the current licensed dose, suggesting that the findings are relevant to clinical practice.",
            "startOffset": 31159,
            "title": "Discussion"
        },
        {
            "endOffset": 32766,
            "parents": [],
            "secId": "sec3",
            "sentence": "Furthermore, we have considered efficacy as objective (clear/nearly clear) and subjective (DLQI) outcomes, and jointly ranked these outcomes using cluster analysis with a proxy marker of tolerability.",
            "startOffset": 32566,
            "title": "Discussion"
        },
        {
            "endOffset": 23731,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.3",
            "sentence": "There was a low risk of reporting bias.",
            "startOffset": 23692,
            "title": "Risk of bias"
        },
        {
            "endOffset": 19186,
            "parents": [],
            "secId": "sec1",
            "sentence": "Traditional pairwise meta-analyses of such trials are useful in summarizing these data; however, their application to practical clinical decision making is challenging when there are multiple treatments and multiple outcomes to consider.",
            "startOffset": 18949,
            "title": "Introduction"
        },
        {
            "endOffset": 28432,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "bib22": {
                    "endOffset": 28402,
                    "startOffset": 28383
                }
            },
            "secId": "sec2.7",
            "sentence": "Visual inspection of the PASI 75 forest plot (Supplementary Figure S8 online) generally suggested consistency between direct and indirect results; however, the effect of methotrexate and/or Study 40 (Saurat et al., 2008) appeared to be inconsistent.",
            "startOffset": 28183,
            "title": "Inconsistency"
        },
        {
            "endOffset": 35343,
            "parents": [],
            "refoffsets": {
                "bib2": {
                    "endOffset": 35341,
                    "startOffset": 35301
                },
                "bib22": {
                    "endOffset": 35341,
                    "startOffset": 35301
                }
            },
            "secId": "sec3",
            "sentence": "Only two RCTs included a methotrexate arm (Barker et al., 2011; Saurat et al., 2008).",
            "startOffset": 35258,
            "title": "Discussion"
        },
        {
            "endOffset": 39132,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.1",
            "sentence": "The title and abstract of studies were screened by two assessors (ZZNY and ZKJ-L), with any disagreement reviewed by a third assessor (CHS).",
            "startOffset": 38992,
            "title": "Search and study selection"
        },
        {
            "endOffset": 25386,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.4",
            "sentence": "This equates to a numbers needed to treat of 4 (95% CI 3, 7) for the ixekizumab-ustekinumab comparison (Table 1).",
            "startOffset": 25273,
            "title": "Efficacy of biologic treatments at 12 to 16 weeks"
        },
        {
            "endOffset": 31158,
            "parents": [],
            "refoffsets": {
                "bib25": {
                    "endOffset": 31156,
                    "startOffset": 31138
                }
            },
            "secId": "sec3",
            "sentence": "For example, in rheumatoid arthritis, an increased risk of serious infections appears to be dose related (Singh et al., 2015).",
            "startOffset": 31032,
            "title": "Discussion"
        },
        {
            "endOffset": 33843,
            "parents": [],
            "secId": "sec3",
            "sentence": "The withdrawal due to adverse event results may be less reliable due to the low number of events (generally between 1 and 2%), reflected in the wide CI of the estimates (Supplementary Figure S8).",
            "startOffset": 33648,
            "title": "Discussion"
        },
        {
            "endOffset": 21521,
            "parents": [],
            "secId": "sec1",
            "sentence": "We also considered the absolute effects of the various treatments to provide meaningful information to support decision making.",
            "startOffset": 21394,
            "title": "Introduction"
        },
        {
            "endOffset": 25987,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.5",
            "sentence": "Ustekinumab performed best (SUCRA 82.3) and infliximab worst (SUCRA 3.5) (Table 2, Supplementary Figure S14 online).",
            "startOffset": 25871,
            "title": "Tolerability of biologic treatments at 12 to 16 weeks"
        },
        {
            "endOffset": 30777,
            "parents": [],
            "secId": "sec3",
            "sentence": "In absolute terms, this equates to an NNH of 25 compared with adalimumab, and an NNH of 18 compared with secukinumab, implying that 18 additional people would need to be treated with ixekizumab compared with secukinumab to result in one additional withdrawal due to adverse events.",
            "startOffset": 30496,
            "title": "Discussion"
        },
        {
            "endOffset": 35640,
            "parents": [],
            "refoffsets": {
                "bib2": {
                    "endOffset": 35453,
                    "startOffset": 35434
                }
            },
            "secId": "sec3",
            "sentence": "The direct comparison between infliximab and methotrexate comes from the RESTORE-1 study (Barker et al., 2011) where all patients were methotrexate-na\u00efve, which is slightly unusual compared with other studies of biologics, and may overestimate the effect of infliximab compared with methotrexate.",
            "startOffset": 35344,
            "title": "Discussion"
        },
        {
            "endOffset": 39320,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.1",
            "sentence": "Selected RCTs were distributed amongst the co-authors for detailed appraisal and extraction of data using a standardized data extraction tool and the extractions checked by another (LSE).",
            "startOffset": 39133,
            "title": "Search and study selection"
        },
        {
            "endOffset": 35257,
            "parents": [],
            "secId": "sec3",
            "sentence": "Consistency was generally acceptable apart from for PASI 75 where the results should be interpreted with caution because of inconsistency within the infliximab-methotrexate-placebo closed loop.",
            "startOffset": 35064,
            "title": "Discussion"
        },
        {
            "endOffset": 27547,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.7",
            "sentence": "Overall tests of consistency and visual inspection of the forest plots (Supplementary Figures S9 and S10 online) did not identify statistically significant inconsistency for mean change in DLQI (\u03c72(2) = 1.45, P = 0.485) (Supplementary Figure S19 online), or withdrawal due to adverse events (\u03c72(9) = 5.56, P = 0.783) (Supplementary Figure S20 online).",
            "startOffset": 27196,
            "title": "Inconsistency"
        },
        {
            "endOffset": 38466,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.1",
            "sentence": "PASI 75 was considered \u201cimportant\u201d rather than \u201ccritical.\u201d",
            "startOffset": 38408,
            "title": "Search and study selection"
        },
        {
            "endOffset": 24129,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.3",
            "sentence": "There was no apparent asymmetry for the studies examining biologic therapies versus placebo at 12 to 16 weeks for any of the outcomes (Supplementary Figures S21\u2013S24 online).",
            "startOffset": 23956,
            "title": "Risk of bias"
        },
        {
            "endOffset": 32158,
            "parents": [],
            "secId": "sec3",
            "sentence": "Similarly, caution should be applied to the interpretation of the change in DLQI outcome data due to possible variation in baseline values for this change score.",
            "startOffset": 31997,
            "title": "Discussion"
        },
        {
            "endOffset": 29067,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.8",
            "sentence": "For the outcome of withdrawal due to adverse events, Etanercept performed best (SUCRA 77.8) and methotrexate worst (SUCRA 6.7).",
            "startOffset": 28940,
            "title": "Subgroup analysis"
        },
        {
            "endOffset": 40490,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "refoffsets": {
                "bib21": {
                    "endOffset": 40488,
                    "startOffset": 40468
                }
            },
            "secId": "sec4.2",
            "sentence": "Rankings were quantified by the SUCRAs that express the percentage (0\u2013100%) of efficacy/safety each treatment has compared with an ideal treatment ranked always first without uncertainty (Salanti et al., 2011).",
            "startOffset": 40280,
            "title": "Data analysis and quality assessment of evidence"
        },
        {
            "endOffset": 18103,
            "parents": [],
            "secId": "sec1",
            "sentence": "Biologic therapies have revolutionized the treatment of moderate-severe psoriasis over the last decade.",
            "startOffset": 18000,
            "title": "Introduction"
        },
        {
            "endOffset": 29933,
            "parents": [],
            "secId": "sec3",
            "sentence": "Of the best overall performing treatments, approximately five additional patients would need to be treated with secukinumab compared with adalimumab, and six with secukinumab compared with ustekinumab to achieve clearance or near clearance for an additional patient, with no significant difference in tolerability.",
            "startOffset": 29619,
            "title": "Discussion"
        },
        {
            "endOffset": 22484,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.1",
            "sentence": "Most trials (38/41 [93%]) were two-arm studies and the rest were three-arm studies.",
            "startOffset": 22401,
            "title": "Study selection and characteristics"
        },
        {
            "endOffset": 26365,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.6",
            "sentence": "Adalimumab, infliximab, ixekizumab, secukinumab, and ustekinumab were all similar with regard to these two efficacy parameters.",
            "startOffset": 26238,
            "title": "Joint rankings of efficacy and tolerability"
        },
        {
            "endOffset": 22799,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.1",
            "sentence": "Five trials (12%) did not state previous biologic therapy use.",
            "startOffset": 22737,
            "title": "Study selection and characteristics"
        },
        {
            "endOffset": 39924,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.2",
            "sentence": "Geometry of the networks was assessed through visual inspection of network maps.",
            "startOffset": 39844,
            "title": "Data analysis and quality assessment of evidence"
        },
        {
            "endOffset": 40674,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.2",
            "sentence": "Outcomes were jointly ranked using the hierarchical cluster analysis of the SUCRA values of each outcome using the clusterank command.",
            "startOffset": 40540,
            "title": "Data analysis and quality assessment of evidence"
        },
        {
            "endOffset": 37820,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.1",
            "sentence": "The patient population included all people with psoriasis of any severity being treated primarily for their skin disease.",
            "startOffset": 37699,
            "title": "Search and study selection"
        },
        {
            "endOffset": 31913,
            "parents": [],
            "secId": "sec3",
            "sentence": "The differences may be true differences due to different doses or may reflect the reduced precision seen in the smaller network of studies looking at just licensed doses, particularly for this less frequent outcome.",
            "startOffset": 31698,
            "title": "Discussion"
        },
        {
            "endOffset": 33395,
            "parents": [],
            "secId": "sec3",
            "sentence": "For completeness, we decided to combine data on all treatment doses; however, there may be important dose-dependent effects on efficacy and safety.",
            "startOffset": 33248,
            "title": "Discussion"
        },
        {
            "endOffset": 42045,
            "parents": [],
            "secId": "sec5",
            "sentence": "A. David Burden: http://orcid.org/0000-0001-7395-9931",
            "startOffset": 41992,
            "title": "ORCIDs"
        },
        {
            "endOffset": 34355,
            "parents": [],
            "secId": "sec3",
            "sentence": "This could suggest evidence of publication bias in favor of small studies that show a beneficial effect of the established comparator, potentially underestimating the effects of newer treatments.",
            "startOffset": 34160,
            "title": "Discussion"
        },
        {
            "endOffset": 41100,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.2",
            "sentence": "Absolute effects were calculated from relative effects estimates based on the assumed control risk across all studies of that comparator using GRADEPro GDT (McMaster University).",
            "startOffset": 40922,
            "title": "Data analysis and quality assessment of evidence"
        },
        {
            "endOffset": 37214,
            "parents": [],
            "secId": "sec3",
            "sentence": "Overall, these results need to be considered alongside real-world, long-term safety and effectiveness data to inform shared decision making.",
            "startOffset": 37074,
            "title": "Discussion"
        },
        {
            "endOffset": 18948,
            "parents": [],
            "secId": "sec1",
            "sentence": "Patients and clinicians are reliant on extrapolating data on average effects from randomized controlled trials (RCTs) to help inform their decision-making process.",
            "startOffset": 18785,
            "title": "Introduction"
        },
        {
            "endOffset": 22736,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.1",
            "sentence": "Only 12 of 41 (29%) trials excluded patients with previous biologic therapy use, and in trials that allowed previous biologic use, the percentages ranged from 1.6 to 64.3%.",
            "startOffset": 22564,
            "title": "Study selection and characteristics"
        },
        {
            "endOffset": 27040,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.6",
            "sentence": "Etanercept, methotrexate, and placebo formed another cluster, characterized by poorer efficacy and moderate tolerability.",
            "startOffset": 26919,
            "title": "Joint rankings of efficacy and tolerability"
        },
        {
            "endOffset": 22894,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.2",
            "sentence": "Placebo-controlled comparisons were available for all treatments and outcomes.",
            "startOffset": 22816,
            "title": "Network structure"
        },
        {
            "endOffset": 18283,
            "parents": [],
            "secId": "sec1",
            "sentence": "The first monoclonal antibodies targeting the tumor necrosis factor-alpha pathway were licensed in 2004 and, more recently, antibodies to IL-12/23 and IL-17A have been introduced.",
            "startOffset": 18104,
            "title": "Introduction"
        },
        {
            "endOffset": 33029,
            "parents": [],
            "secId": "sec3",
            "sentence": "There are some key limitations to the interpretation of these results.",
            "startOffset": 32959,
            "title": "Discussion"
        },
        {
            "endOffset": 34437,
            "parents": [],
            "secId": "sec3",
            "sentence": "Consistency and transitivity are important assumptions for the validity of an NMA.",
            "startOffset": 34355,
            "title": "Discussion"
        },
        {
            "endOffset": 27940,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "bib7": {
                    "endOffset": 27904,
                    "startOffset": 27883
                }
            },
            "secId": "sec2.7",
            "sentence": "There was no overall statistically significant inconsistency for the outcome of clear/nearly clear (\u03c72(9) = 8.84, P = 0.453); however, visual inspection of the forest plot (Supplementary Figure S7 online) suggested possible inconsistency (inconsistency factor 0.63, 95% CI 0.08, 1.18) in study 6, comparing infliximab with etanercept (de Vries et al., 2017) (Supplementary Figure S17 online).",
            "startOffset": 27548,
            "title": "Inconsistency"
        },
        {
            "endOffset": 39997,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.2",
            "sentence": "Summary results were presented as an odds ratio, or mean, with a 95% CI.",
            "startOffset": 39925,
            "title": "Data analysis and quality assessment of evidence"
        },
        {
            "endOffset": 38651,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.1",
            "sentence": "RCTs of any duration beyond 12 weeks were included.",
            "startOffset": 38600,
            "title": "Search and study selection"
        },
        {
            "endOffset": 41337,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "refoffsets": {
                "bib12": {
                    "endOffset": 41335,
                    "startOffset": 41315
                }
            },
            "secId": "sec4.2",
            "sentence": "Study quality was evaluated using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins et al., 2011).",
            "startOffset": 41193,
            "title": "Data analysis and quality assessment of evidence"
        },
        {
            "endOffset": 41429,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.2",
            "sentence": "Heterogeneity and inconsistency were evaluated using visual inspection of the forest plots.",
            "startOffset": 41338,
            "title": "Data analysis and quality assessment of evidence"
        },
        {
            "endOffset": 35890,
            "parents": [],
            "secId": "sec3",
            "sentence": "It is also important to remember that these are average effects and individual patients may experience different results.",
            "startOffset": 35769,
            "title": "Discussion"
        },
        {
            "endOffset": 38599,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.1",
            "sentence": "The primary safety outcome was tolerability, measured by withdrawal due to adverse events, and this was also considered \u201cimportant.\u201d",
            "startOffset": 38467,
            "title": "Search and study selection"
        },
        {
            "endOffset": 19819,
            "parents": [],
            "refoffsets": {
                "bib18": {
                    "endOffset": 19817,
                    "startOffset": 19799
                }
            },
            "secId": "sec1",
            "sentence": "A useful way of understanding the differences between treatments is to perform a systematic review of the current evidence and a network meta-analysis (NMA), where a connecting network of evidence allows for comparisons to be made between all available interventions and a relative ranking of treatments produced (Mills et al., 2013).",
            "startOffset": 19485,
            "title": "Introduction"
        },
        {
            "endOffset": 27183,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.6",
            "sentence": "The same groupings were identified when comparing mean change in DLQI with withdrawal due to adverse events (Supplementary Figure S15 online).",
            "startOffset": 27041,
            "title": "Joint rankings of efficacy and tolerability"
        },
        {
            "endOffset": 39554,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "refoffsets": {
                "bib27": {
                    "endOffset": 39552,
                    "startOffset": 39518
                },
                "bib6": {
                    "endOffset": 39552,
                    "startOffset": 39518
                }
            },
            "secId": "sec4.2",
            "sentence": "NMA was performed using a random-effects model within a frequentist approach in Stata 13 (Stata Corp, College Station, TX) using the network command (Chaimani et al., 2014; White, 2011).",
            "startOffset": 39368,
            "title": "Data analysis and quality assessment of evidence"
        },
        {
            "endOffset": 22563,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.1",
            "sentence": "All studies included patients with previous conventional systemic therapy use.",
            "startOffset": 22485,
            "title": "Study selection and characteristics"
        },
        {
            "endOffset": 36475,
            "parents": [],
            "secId": "sec3",
            "sentence": "In terms of research implications, on the basis of these findings, we would argue that the use of placebo as a comparator is no longer ethical for RCTs that examine treatment efficacy as there is no clinical equipoise regarding the short-term relative efficacy of any of the biologic treatments compared with placebo.",
            "startOffset": 36158,
            "title": "Discussion"
        },
        {
            "endOffset": 18784,
            "parents": [],
            "secId": "sec1",
            "sentence": "Given this choice, the challenge is in deciding which treatment to use for which patients.",
            "startOffset": 18694,
            "title": "Introduction"
        },
        {
            "endOffset": 37411,
            "parents": [],
            "refoffsets": {
                "bib13": {
                    "endOffset": 37409,
                    "startOffset": 37390
                }
            },
            "secId": "sec4",
            "sentence": "We conducted a systematic review to examine the efficacy and tolerability of biologic therapies for psoriasis in accordance with the PRISMA-NMA statement (Hutton et al., 2015).",
            "startOffset": 37235,
            "title": "Materials and Methods"
        },
        {
            "endOffset": 20554,
            "parents": [],
            "refoffsets": {
                "bib26": {
                    "endOffset": 20552,
                    "startOffset": 20530
                }
            },
            "secId": "sec1",
            "sentence": "Treatment tolerability is an important consideration for patients, with such concerns directly influencing whether patients adhere to treatment after initiation (Thorneloe et al., 2016).",
            "startOffset": 20368,
            "title": "Introduction"
        },
        {
            "endOffset": 23135,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.2",
            "sentence": "There were also direct comparisons between methotrexate and adalimumab or infliximab.",
            "startOffset": 23050,
            "title": "Network structure"
        },
        {
            "endOffset": 21227,
            "parents": [],
            "secId": "sec1",
            "sentence": "Here we have reviewed the currently available RCT evidence to assess the efficacy and tolerability of licensed biologic therapies for skin psoriasis\u2014adalimumab, etanercept, infliximab, secukinumab, ustekinumab, and ixekizumab\u2014compared with each other, placebo, or methotrexate.",
            "startOffset": 20950,
            "title": "Introduction"
        },
        {
            "endOffset": 34019,
            "parents": [],
            "secId": "sec3",
            "sentence": "Although the hierarchical cluster analysis results offer an objective way of combining different outcome measures, individual patients may prioritize one outcome over another.",
            "startOffset": 33844,
            "title": "Discussion"
        },
        {
            "endOffset": 36158,
            "parents": [],
            "refoffsets": {
                "bib11": {
                    "endOffset": 36156,
                    "startOffset": 36134
                }
            },
            "secId": "sec3",
            "sentence": "Efforts are underway to stratify groups of patients receiving biologic treatments for psoriasis to predict which treatments will perform best with which treatments, such as the psoriasis stratification to optimize relevant therapy initiative (Griffiths et al., 2015).",
            "startOffset": 35891,
            "title": "Discussion"
        },
        {
            "endOffset": 19317,
            "parents": [],
            "secId": "sec1",
            "sentence": "The issue is compounded by the paucity of direct head-to-head active-comparator RCTs needed to inform such pairwise meta-analyses.",
            "startOffset": 19187,
            "title": "Introduction"
        },
        {
            "endOffset": 25747,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.5",
            "sentence": "Compared with etanercept, infliximab was associated with statistically significant increased odds of withdrawal due to adverse events.",
            "startOffset": 25613,
            "title": "Tolerability of biologic treatments at 12 to 16 weeks"
        },
        {
            "endOffset": 29174,
            "parents": [],
            "secId": "sec3",
            "sentence": "We have performed a comprehensive NMA comparing biologic therapies for moderate-severe psoriasis.",
            "startOffset": 29077,
            "title": "Discussion"
        },
        {
            "endOffset": 29619,
            "parents": [],
            "secId": "sec3",
            "sentence": "The identification of three distinct groups of treatments based on efficacy and tolerability provides an objective way of considering the relative strengths and weaknesses of the different biologics.",
            "startOffset": 29420,
            "title": "Discussion"
        },
        {
            "endOffset": 21961,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.1",
            "sentence": "Forty-five studies were selected for inclusion (Supplementary Appendix S1 online), presenting data on direct comparisons from 41 RCTs (20,561 participants) (see Figure 1).",
            "startOffset": 21790,
            "title": "Study selection and characteristics"
        },
        {
            "endOffset": 23620,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.3",
            "sentence": "A total of 38 of 41 RCTs (93%) had a low risk of detection bias and 35 of 41 RCTs (85%) had a low risk of attrition bias.",
            "startOffset": 23499,
            "title": "Risk of bias"
        },
        {
            "endOffset": 30927,
            "parents": [],
            "secId": "sec3",
            "sentence": "It is not clear what is driving the relatively poor tolerability of ixekizumab as the reasons for withdrawal were not stated in the published papers.",
            "startOffset": 30778,
            "title": "Discussion"
        },
        {
            "endOffset": 23691,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.3",
            "sentence": "All studies were financially sponsored by the pharmaceutical industry.",
            "startOffset": 23621,
            "title": "Risk of bias"
        },
        {
            "endOffset": 39680,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "refoffsets": {
                "bib18": {
                    "endOffset": 39678,
                    "startOffset": 39660
                }
            },
            "secId": "sec4.2",
            "sentence": "NMA synthesizes direct and indirect evidence in a network of trials that compare multiple interventions (Mills et al., 2013).",
            "startOffset": 39555,
            "title": "Data analysis and quality assessment of evidence"
        },
        {
            "endOffset": 24405,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.4",
            "sentence": "All biologic therapies and methotrexate had statistically significant increased odds of clear/nearly clear, PASI 75, and mean change in DLQI compared with placebo at 12 to 16 weeks (Table 1, Supplementary Figures S3\u2013S5 online).",
            "startOffset": 24178,
            "title": "Efficacy of biologic treatments at 12 to 16 weeks"
        },
        {
            "endOffset": 25272,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.4",
            "sentence": "In absolute terms, there was a difference of 112 (95% confidence interval [CI] \u221221, 231) more people per 1,000 achieving clear/nearly clear with ixekizumab compared with secukinumab, or 259 (95% CI 155, 341) more people per 1,000 with ixekizumab compared with ustekinumab.",
            "startOffset": 25000,
            "title": "Efficacy of biologic treatments at 12 to 16 weeks"
        },
        {
            "endOffset": 28669,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.7",
            "sentence": "Loop-specific inconsistency was examined for PASI 75 and confirmed a significantly raised inconsistency factor in the placebo-infliximab-methotrexate loop (inconsistency factor 2.31, 95% CI 1.24, 3.39) (Supplementary Figure S18 online).",
            "startOffset": 28433,
            "title": "Inconsistency"
        },
        {
            "endOffset": 38765,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.1",
            "sentence": "Studies were excluded if there were <50 participants.",
            "startOffset": 38712,
            "title": "Search and study selection"
        },
        {
            "endOffset": 22337,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.1",
            "sentence": "Detailed characteristics of the included studies are given in Supplementary Table S1 (online).",
            "startOffset": 22243,
            "title": "Study selection and characteristics"
        },
        {
            "endOffset": 28939,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.8",
            "sentence": "Relative rankings were the same as for the main analysis for the efficacy outcomes (Supplementary Table S4 online).",
            "startOffset": 28824,
            "title": "Subgroup analysis"
        },
        {
            "endOffset": 21789,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.1",
            "sentence": "After deduplication, 5,915 studies were identified on searching.",
            "startOffset": 21725,
            "title": "Study selection and characteristics"
        },
        {
            "endOffset": 23049,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.2",
            "sentence": "Direct active comparisons between biologics were limited to ixekizumab, ustekinumab, or secukinumab versus etanercept, and ustekinumab versus secukinumab.",
            "startOffset": 22895,
            "title": "Network structure"
        },
        {
            "endOffset": 29419,
            "parents": [],
            "secId": "sec3",
            "sentence": "This NMA includes the newly licensed anti-IL-17A monoclonal antibody, ixekizumab, and considers joint rankings of multiple outcomes for psoriasis, including DLQI, and to provide absolute effect estimates to help inform clinical decision making.",
            "startOffset": 29175,
            "title": "Discussion"
        },
        {
            "endOffset": 42160,
            "parents": [],
            "secId": "sec5",
            "sentence": "Catherine H. Smith: http://orcid.org/0000-0001-9918-1144",
            "startOffset": 42104,
            "title": "ORCIDs"
        },
        {
            "endOffset": 41193,
            "parents": [
                {
                    "id": "sec4",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec4.2",
            "sentence": "Numbers needed to treat or harm were calculated as the reciprocal of the corresponding risk.",
            "startOffset": 41101,
            "title": "Data analysis and quality assessment of evidence"
        }
    ],
    "docId": "S0022202X17314276",
    "metadata": {
        "asjc": [
            "1303",
            "1307",
            "1312",
            "2708"
        ],
        "authors": [
            {
                "email": null,
                "first": "Zarif K.",
                "initial": "Z.K.",
                "last": "Jabbar-Lopez"
            },
            {
                "email": null,
                "first": "Zenas Z.N.",
                "initial": "Z.Z.N.",
                "last": "Yiu"
            },
            {
                "email": null,
                "first": "Victoria",
                "initial": "V.",
                "last": "Ward"
            },
            {
                "email": null,
                "first": "Lesley S.",
                "initial": "L.S.",
                "last": "Exton"
            },
            {
                "email": null,
                "first": "M. Firouz",
                "initial": "M.F.",
                "last": "Mohd Mustapa"
            },
            {
                "email": null,
                "first": "Eleanor",
                "initial": "E.",
                "last": "Samarasekera"
            },
            {
                "email": null,
                "first": "A. David",
                "initial": "A.D.",
                "last": "Burden"
            },
            {
                "email": null,
                "first": "Ruth",
                "initial": "R.",
                "last": "Murphy"
            },
            {
                "email": null,
                "first": "Caroline M.",
                "initial": "C.M.",
                "last": "Owen"
            },
            {
                "email": null,
                "first": "Richard",
                "initial": "R.",
                "last": "Parslew"
            },
            {
                "email": null,
                "first": "Vanessa",
                "initial": "V.",
                "last": "Venning"
            },
            {
                "email": null,
                "first": "Richard B.",
                "initial": "R.B.",
                "last": "Warren"
            },
            {
                "email": "catherine.smith@kcl.ac.uk",
                "first": "Catherine H.",
                "initial": "C.H.",
                "last": "Smith"
            }
        ],
        "doi": "10.1016/j.jid.2017.04.009",
        "firstpage": "1646",
        "issn": "0022202X",
        "lastpage": "1654",
        "openaccess": "Full",
        "pub_year": 2017,
        "subjareas": [
            "BIOC",
            "MEDI"
        ],
        "title": "Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis"
    }
}